Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.62 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.62 |
| ▸ | GABRP | O00591 | 2/20 | 0.62 |
| ▸ | GABRD | O14764 | 2/20 | 0.62 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.62 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.62 |
| ▸ | GABRE | P78334 | 2/20 | 0.62 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.62 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.62 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.62 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.62 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7499590 | 0.79 | GABRA1 (0.53) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL1648642 | 0.78 | GABRP (0.58) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL7390689 | 0.78 | P4HTM (0.55) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL7017455 | 0.77 | GABRP (0.52) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL1404488 | 0.77 | GABRA1 (0.52) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL23286878 | 0.77 | GABRA1 (0.52) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL2648712 | 0.77 | GABRP (1.00) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL14107961 | 0.75 | CDK2 (0.53) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| Hydrochloric Acid SCHEMBL1712322 | 0.75 | GABRP (0.96) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL12304432 | 0.74 | GABRP (0.48) | GABRA5GABRB2GABRA1GABRA4GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117343556-A | Bio-based compound modified cracking carbon black and application thereof in tire preparation | 中策橡胶集团股份有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-117247639-A | Tire inner liner rubber composition containing bio-based modified cracking carbon black, mixing method and tire | 中策橡胶集团股份有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-117247608-A | Tire pad rubber composition containing bio-based modified cracking carbon black, mixing method and tire | 中策橡胶集团股份有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-117343556-A | Bio-based compound modified cracking carbon black and application thereof in tire preparation | 中策橡胶集团股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117247608-A | Tire pad rubber composition containing bio-based modified cracking carbon black, mixing method and tire | 中策橡胶集团股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-117247639-A | Tire inner liner rubber composition containing bio-based modified cracking carbon black, mixing method and tire | 中策橡胶集团股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-112778212-B | Synthesis method of cropanisin intermediate 2-aminopyrimidine-5-methyl carboxylate | 苏州莱克施德药业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-112778212-B | Synthesis method of cropanisin intermediate 2-aminopyrimidine-5-methyl carboxylate | 苏州莱克施德药业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-112778212-B | Synthesis method of cropanisin intermediate 2-aminopyrimidine-5-methyl carboxylate | 苏州莱克施德药业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-112778212-A | Synthesis method of cropanisin intermediate 2-aminopyrimidine-5-methyl carboxylate | 苏州莱克施德药业有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-112778212-A | Synthesis method of cropanisin intermediate 2-aminopyrimidine-5-methyl carboxylate | 苏州莱克施德药业有限公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-1664032-A1 | N-SUBSTITUTED PYRAZOLYL-AMIDYL-BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1658289-A2 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060035951-A1 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | BOLGER JOSHUA | 2006-02-16 | — | — | US | disclosed |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | CASTELHANO ARLINDO L | 2006-02-16 | — | — | US | disclosed |
| WO-2005021544-A2 | N3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021537-A1 | N-SUBSTITUTED PYRAZOLYL-AMIDYL-BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021531-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-6329383-B1 | THESE COMPOUNDS ARE USEFUL AS A HUMAN GROWTH HORMONE (HGH) MIMETIC, WHICH TRIGGER GH AGONIST EFFECTS IN ANIMALS AND ESPECIALLY AS AN ORALLY AVAILABLE HUMAN GROWTH HORMONE (HGH). | PHARMACIA AB (SE) | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | KIT, ABL1, CHUK | GABRA5 3064/4885GABRB2 2848/4885GABRA1 3329/4885 |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | KIT, CHUK, TNNI3K | GABRA5 3033/4885GABRB2 1678/4885GABRA1 2772/4885 |
| US-20060035951-A1 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | KIT, TNNI3K, CHUK | GABRA5 3140/4885GABRB2 2401/4885GABRA1 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.